New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
06:35 EDTVICLVical reports Q4 EPS (9c), consensus (10c)
Reports Q4 revenue $2.32M, consensus $1.64M.
News For VICL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
05:32 EDTVICLVical and Anges announce collaboration to develop therapy for ebola virus
Vical and AnGes announced that they have entered into collaboration to develop and commercialize an equine polyclonal antibody therapy for patients afflicted with Ebola virus disease. No medicines or vaccines are currently approved for the treatment of Ebola. The planned approach will be to isolate antibodies from the horses immunized with a DNA vaccine encoding an Ebola virus glycoprotein antigen. The antibodies will be purified and developed for the treatment of Ebola virus disease in humans. Under the agreement, Vical will develop and provide to AnGes a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola virus, formulated with Vical's proprietary Vaxfectin adjuvant. AnGes will receive the right to exclusively develop and commercialize the equine polyclonal antibody therapy in Japan and will be responsible for all development costs. Vical will receive an upfront payment and is eligible to receive royalties on net sales and a percentage of payments received by AnGes under any sub-licensing agreements.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use